Hong Kong-listed Wai Chun Bio-Technology Limited (“Wai Chun Bio-Tech”) has signed a three-year Authorized Overseas Master Agency Agreement with Henan Mine Crane Co., Ltd. on 5 August 2026, granting Wai Chun Bio-Tech exclusive distribution rights for all crane and mining-equipment products outside Mainland China.
Key terms • Scope and territory: The mandate covers all bridge cranes, gantry cranes, electric hoists and related accessories under the “Kuangyuan” brand across every country and region except Mainland China. • Exclusivity: Henan Mine Crane will not supply the authorised products to other third parties in the covered markets during the contract period. • Term: 5 August 2026 – 5 August 2029, with Wai Chun Bio-Tech holding a right of first refusal for renewal on identical terms. • Pricing model: Henan Mine Crane will supply goods at a “market-competitive floor price”; Wai Chun Bio-Tech sets final resale prices independently and retains the full sales premium. Settlements will be in T/T or L/C.
Henan Mine Crane snapshot Founded in 2002, the Authorizing Party is described as a national high-tech leader in China’s crane industry, with: • Registered capital of RMB 1.18 billion • Construction area of 1.62 million sq m • Workforce exceeding 4,700 employees • Annual production and sales of more than 100,000 units • Annual revenue of roughly RMB 6.50 billion and net profit of about RMB 460 million
Strategic implications for Wai Chun Bio-Tech 1. Channel–manufacturing integration: The agreement leverages Henan Mine Crane’s manufacturing scale and Wai Chun Bio-Tech’s overseas network to build a global sales platform from Hong Kong. 2. Exposure to infrastructure demand: Exclusive rights position Wai Chun Bio-Tech to capture rising crane demand driven by international infrastructure projects and the Belt and Road initiative. 3. Asset-light margin profile: Access to floor-price supply while retaining full pricing discretion offers a high-margin, cash-generative expansion path without manufacturing capex.
Management views the terms as fair, reasonable and beneficial to shareholders. Operational results will depend on actual overseas orders; investors are advised to exercise caution when trading the company’s securities.